SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway

• Published in: Journal of experimental & clinical cancer research Vol. 39; no. 1; p. 79
• Main Authors: Zhang, Jing, Liu, Xiao-Han, Li, Cong, Wu, Xiao-Xing, Chen, Yan-Lin, Li, Wen-Wen, Li, Xian, Gong, Fan, Tang, Qin, Jiang, Dan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.05.2020; BioMed Central; BMC
• Subjects: Analysis; Antibodies; Cancer metastasis; Cancer therapies; Cell adhesion & migration; Cell growth; Chemotherapy; Gynecology; High-grade serous ovarian cancer; Immunohistochemistry; Kinases; Medical prognosis; Medical research; Metastasis; Metastasis PI3K/Akt; Ovarian cancer; Prognosis; Progression; Proteins; SNCG; China; United Kingdom > UK; United States > US; Japan; Metastasis PI3K/Akt; Progression; SNCG; High-grade serous ovarian cancer
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-020-01589-9

The poor prognosis of patients with ovarian cancer is mainly due to cancer progression. γ-Synuclein (SNCG) has reported as a critical player in cancer metastasis. However, its biological roles and mechanism are yet incompletely understood in ovarian cancer, especially in high-grade serous ovarian cancer (HGSOC). This is a retrospective study of 312 patients with ovarian cancer at a single center between 2006 and 2016. Ovarian cancer tissues were stained by immunohistochemistry to analyze the relationship between SNCG expression and clinicopathologic factors. The clinical outcomes versus SNCG expression level were evaluated by Kaplan-Meier method and multiple Cox regression analysis. Next, systematical functional experiments were given to examine the proliferation and metastatic abilities of SNCG both in vitro and in vivo using loss- and gain- of function approaches. Furthermore, the mechanisms of SNCG overexpression were examined by human phospho-kinase array kit and western blot analysis. Clinically, the expression of SNCG was significantly upregulated in ovarian cancer compared with the borderline and benign tumor, normal ovary, and fallopian tube. Notably, the high level of SNCG correlated with high-risk clinicopathologic features and showed poor survival for patients with HGSOC, indicating an independent prognostic factor for these patients. Functionally, we observed that overexpression of SNCG promoted cell proliferation, tumor formation, migration, and invasion both in vitro and in vivo. Mechanistically, we identified that SNCG promoted cancer cell metastasis through activating the PI3K/AKT signaling pathway. Our results reveal SNCG up-regulation contributes to the poor clinical outcome of patients with HGSOC and highlight the metastasis-promoting function of SNCG via activating the PI3K/Akt signaling pathway in HGSOC.